A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
CancerNeoplasmsTumors
Interventions
DRUG

OSI-906 and Pemetrexed

"Pemetrexed will be administered intravenously on day 1 of cycle 1 at a dose of 500 mg/m2 as a 10-minute infusion. Subsequent doses will be defined by tolerability.~OSI-906 will be administered orally twice daily (12 hours apart) at approximately the same times each day on a continuous schedule, beginning on Day 0 of cycle 1."

Trial Locations (1)

30322

Winship Cancer Institute of Emory University, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

Emory University

OTHER

NCT01567384 - A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies | Biotech Hunter | Biotech Hunter